Trevi Therapeutics (TRVI) Long-Term Debt Repayments (2018 - 2023)

Trevi Therapeutics' (TRVI) quarterly Long-Term Debt Repayments came in at $7.7 million in Q2 2023, up 337.66% year-on-year from $1.8 million in Q2 2022, and up 337.66% quarter-over-quarter from $1.8 million in Q1 2023.

Trevi Therapeutics (TRVI) Long-Term Debt Repayments (2018 - 2023) Analysis & Trends

Trevi Therapeutics' Long-Term Debt Repayments history runs 3 years deep, the most recent figure standing at $7.7 million for Q2 2023.

  • On a quarterly basis, Long-Term Debt Repayments rose 337.66% year-over-year to $7.7 million in Q2 2023; TTM through Sep 2023 was $11.2 million, a 173.3% increase from a year earlier, with the FY2022 full-year figure at $5.8 million, changed N/A from the prior year.
  • Long-Term Debt Repayments grew to $7.7 million in Q2 2023 per TRVI's latest filing, from $1.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $7.7 million in Q2 2023 and bottomed at $583000.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 7.64 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Trevi Therapeutics 2.50 Bn 2.50 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 7.66 Mn
Jun 30, 2023 7.66 Mn
Mar 31, 2023 1.75 Mn
Mar 31, 2023 1.75 Mn
Dec 31, 2022 1.75 Mn
Dec 31, 2022 1.75 Mn
Sep 30, 2022 1.75 Mn
Sep 30, 2022 1.75 Mn
Jun 30, 2022 1.75 Mn
Jun 30, 2022 1.75 Mn
Mar 31, 2022 583,000.00
Mar 31, 2022 583,000.00
Sep 30, 2018 1,000.00
Sep 30, 2018 1,000.00
Jun 30, 2018 2.75 Mn
Jun 30, 2018 2.75 Mn
Mar 31, 2018 2.06 Mn
Mar 31, 2018 2.06 Mn